Select Page

OUR COMPANY

Contents:

Clinical Advisory Board

John Breitner, MD, MPH

John Breitner is a geriatric psychiatrist and epidemiologist who has devoted his career to Alzheimer’s disease (AD), its risk factors and their implications for its prevention.  He has worked extensively in diagnosis and treatment of patients with dementia but is better known as a researcher.  His work began with studies on familial aggregation in AD and evolved to twin studies of heritability and environmental risk factors.  He then founded the Cache County Study of Memory in Aging, a longitudinal investigation of genetic and environmental antecedents of AD, which has produced over 100 scientific papers.  More recently he has been Chair of the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT), a randomized controlled trial to evaluate nonsteroidal anti-inflammatory drugs as agents for the primary prevention of AD in healthy elderly people.  As that trial is winding down, he has recently joined the McGill faculty as Director of the new Centre for Studies on Prevention of AD (StoP-AD) at the Douglas Mental Health Research Institute.  The Centre is devoted to identification and quantitation of markers of AD in its pre-symptomatic stage, and to preliminary testing of experimental strategies for their capacity to prevent progression of the disease toward the symptomatic illness. Dr. Breitner has authored over 200 publications. He graduated from the University of Pennsylvania and is Board certified in Preventive Medicine, Geriatric Psychiatry and Psychiatry.

Michael Grundman, MD, MPH

President and CEO, Global R&D Partners, LLC

Dr. Grundman is the President and Chief Executive Officer at Global R&D Partners, LLC, a consulting firm that works closely with pharmaceutical and biotechnology companies to develop novel agents for the diagnosis and treatment of serious and life threatening diseases. He previously served as Vice President of Clinical Development at Janssen Alzheimer Immunotherapy, LLC, and Elan Pharmaceuticals, Inc. Prior to joining the pharmaceutical industry, Dr. Grundman was Associate Director of the Alzheimer’s Disease Cooperative Study (ADCS) at the University of California, San Diego (UCSD) and is currently an Adjunct Professor of Neurosciences at UCSD. He received his BA from New York University with Honors in Biochemistry. He obtained an MD and Neurology training at the Albert Einstein College of Medicine and a Master of Public Health degree from Columbia University. Dr. Grundman previously served on the FDA Peripheral and Central Nervous System Advisory Committee and is an inventor on a number of patents related to Alzheimer’s disease therapy. He lectures frequently at national and international scientific meetings and has published over 80 articles related to Alzheimer’s disease and dementia.

Eric M. Reiman, MD

Executive Director, Banner Alzheimer’s Institute

Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer for Banner Research, Clinical Director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and Director of the Arizona Alzheimer’s Consortium. His research interests include brain imaging, genomics, the unusually early detection and tracking of Alzheimer’s disease (AD), the evaluation of genetic and non-genetic risk factors and putative AD-modifying treatments, and the accelerated evaluation of putative treatments to prevent AD. Dr. Reiman received his undergraduate and medical education at Duke University and his psychiatric residency training at Duke and Washington University in St. Louis. He launched his brain imaging research career at Washington University and a statewide collaborative program to help advance AD research and care in Arizona. He is an author of more than 250 publications, principal investigator of several NIH research grants, director of an NIH-sponsored AD Center, a leader of the Alzheimer’s Prevention Initiative (API), and a recipient of the Potamkin Prize for his contributions to AD research.

J. Timothy Greenamyre, MD, PhD

Director, Pittsburgh Institute for Neurodegenerative Diseases

Dr. Tim Greenamyre is the Love Family Professor and vice-chair of neurology, chief of Movement Disorders, and director of the Pittsburgh Institute for Neurodegenerative Diseases (PIND) and the American Parkinson Disease Association Advanced Center for Parkinson’s Disease Research at the University of Pittsburgh. He is Co-Chair of the Parkinson’s Foundation SAB and a member of the SAB of the Michael J. Fox Foundation and the American Parkinson Disease Association. He has been listed as one of the ‘Best Doctors in America’ since the mid-1990s. He is editor-in-chief of the scientific journal Neurobiology of Disease and serves on other editorial boards. His laboratory studies mechanisms of neurodegeneration in Parkinson’s disease, with a focus on gene-environment interactions. Translational studies use pharmacological and ‘gene therapy’ approaches. He is Chair of the 2019 Parkinson’s Disease Gordon Research Conference.

Olivier Rascol, MD, PhD

Departments of Clinical Pharmacology and Neurosciences, Toulouse University Hospital

Dr. Olivier Rascol obtained his MD in Neurology (Toulouse, 1985) and his PhD in Neurosciences (Paris, 1992). He has run the Toulouse Clinical Research Centre since 1994 and the Toulouse European Space Clinic since 1998.  He is the coordinator of the Toulouse Expert Center for Parkinson Disease and of the French Reference Center for Multiple System Atrophy. Dr Rascol is the chair of the NS-Park/F-CRIN Neurosciences Network on clinical research in Parkinson disease and also coordinating the National French Clinical Research Infrastructure Network F-CRIN.  As a neuropharmacologist, Dr. Rascol’s main fields of interest are Parkinson’s disease and movement disorders, drug development for Parkinson’s disease and functional neuroimaging. He is currently running several research programs on neuroprotection, dopamine agonists, dyskinesia and non-dopaminergic antiparkinsonian medications in collaboration with several research centers in the United States and in Europe. He serves as an external advisor for French and European scientific organizations, patients’ associations, drug agencies and international pharmaceutical companies.  Dr Rascol has been deeply involved in the management and organizations of clinical research in France.  Dr Rascol has published more than 450 articles in leading international scientific journals. He has also been invited to give more than 400 lectures.

Donald G. Stein, PhD

Asa G. Candler Professor and Distinguished Professor in Emergency Medicine at the Emory University School of Medicine

Dr. Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer for Banner Research, Clinical Director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and Director of the Arizona Alzheimer’s Consortium. His research interests include brain imaging, genomics, the unusually early detection and tracking of Alzheimer’s disease (AD), the evaluation of genetic and non-genetic risk factors and putative AD-modifying treatments, and the accelerated evaluation of putative treatments to prevent AD. Dr. Reiman received his undergraduate and medical education at Duke University and his psychiatric residency training at Duke and Washington University in St. Louis. He launched his brain imaging research career at Washington University and a statewide collaborative program to help advance AD research and care in Arizona. He is an author of more than 250 publications, principal investigator of several NIH research grants, director of an NIH-sponsored AD Center, a leader of the Alzheimer’s Prevention Initiative (API), and a recipient of the Potamkin Prize for his contributions to AD research.